Lite Strategy, Inc. (NASDAQ:LITS) — Market Cap & Net Worth
Market Cap & Net Worth: Lite Strategy, Inc. (LITS)
Lite Strategy, Inc. (NASDAQ:LITS) has a market capitalization of $38.24 Million ($38.24 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22977 globally and #5027 in its home market, demonstrating a -1.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lite Strategy, Inc.'s stock price $1.04 by its total outstanding shares 36769677 (36.77 Million). Also see LITS total assets for a full breakdown of the balance sheet.
Lite Strategy, Inc. Market Cap History: 2025 to 2026
Lite Strategy, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $48.54 Million to $38.24 Million (0.00% CAGR). Also see Lite Strategy, Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
Lite Strategy, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lite Strategy, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Lite Strategy, Inc. stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LITS by Market Capitalization
Companies near Lite Strategy, Inc. in the global market cap rankings as of September 18, 2026. Review LITS goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lite Strategy, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Lite Strategy, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Lite Strategy, Inc.'s market cap moved from $48.54 Million to $ 38.24 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $38.24 Million | -21.21% |
| 2025 | $48.54 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Lite Strategy, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.24 Million USD |
| MoneyControl | $38.24 Million USD |
| MarketWatch | $38.24 Million USD |
| marketcap.company | $38.24 Million USD |
| Reuters | $38.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.